Kevin C. Gorman

Kevin C. Gorman

DirectoratNeurocrine Biosciences· In proxies 2020–2025

Pay in FY2024Low confidence+2% from the year before · Neurocrine Biosciences stock +3.6% the same year

Kevin C. Gorman was paid $16.0M in FY2024 (Dec), up 2%. Neurocrine Biosciences stock rose 3.6% that year.

Pay$100 in the stock at the end of FY19 → $127
Pay is from the Summary Compensation Table of each Neurocrine Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. XencorPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  2. Neurocrine BiosciencesPublic company · 6 yr
    • Director2020 – Present · 6 yrStock in role +33%
  3. Biotechnology Innovation OrganizationPublic company
    • Director? – PresentNo stock prices for these years
  4. Manufacturers of AmericaPublic company
    • Director? – PresentNo stock prices for these years
  5. Pharmaceutical ResearchPublic company
    • Director? – PresentNo stock prices for these years
  6. Xencor, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?